Category Archives: Reviews

The Respiratory Syncytial Virus (RSV) Surge In 2022

Physicians are reporting high numbers of respiratory illnesses like RSV and the flu earlier than the typical winter peak. WSJ’s Brianna Abbott explains what the early surge means for the coming winter months.

Respiratory syncytial virus (RSV) causes infections of the lungs and respiratory tract. It’s so common that most children have been infected with the virus by age 2. Respiratory syncytial (sin-SISH-ul) virus can also infect adults.

In adults and older, healthy children, RSV symptoms are mild and typically mimic the common cold. Self-care measures are usually all that’s needed to relieve any discomfort.

RSV can cause severe infection in some people, including babies 12 months and younger (infants), especially premature infants, older adults, people with heart and lung disease, or anyone with a weak immune system (immunocompromised).

Read more

Reports: Tufts Health & Nutrition, November 2022

Cover Image

Inside the Tufts Health & Nutrition Letter – November 2022:

  • Give Thanks for Good Health
  • Newsbites: Vitamin D; red meat and CVD risk; psyllium and constipation
  • Grain Products: Don’t be Fooled by Healthy-Sounding Labels!
  • Special Report: Top 3 Reasons to Avoid “Top Foods” Lists
  • Diet and Hemorrhoids
  • Featured Recipe: Fresh Cranberry Orange Relish
  • Ask Tufts Experts: Processed foods; calcium intake

New Diabetes Technology: Abbott’s Freestyle Libre 3 Glucose Monitor Review

Abbott Laboratories newest continuous glucose monitor is now available at participating retail pharmacies and through durable medical equipment suppliers. The Freestyle Libre 3 was approved by the FDA in June and is a step up from previous Abbott systems.

Abbott Laboratories and Dexcom are the leaders in the CGM market, which hit $5.1 billion in revenue in 2021 and is expected to reach $13.2 billion by 2028, according to Vantage Market Research. Abbott’s CGM systems, called FreeStyle Libre, generated $3.7 billion in revenue last year, with 4 million users globally.

CNBC’s Erin Black, a type 1 diabetic, tested out the Libre 3 for over a month. Here is her review.